Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,348 Funding7,268 Clinical research27

Loading search results…

Browse

Scholars8,803 Publications201,348 Funding7,268 Clinical research27

FiltersClear all

Status

Recruiting8
Active, not recruiting5
Completed8
Terminated6

Study type

Interventional25
Expanded access2

Phase

Phase 18
Phase 1/26
Phase 25
Phase 32
Not applicable2
Not reported2

Investigator

Gail J Roboz4
John Allan3
Pinkal Desai3
Ruben Niesvizky3
Ellen K. Ritchie2

Show all 17Show fewer

Department

Medicine25
Neurology2

Condition

Recurrence27
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50Show fewer

Intervention type

Drug23
Biological3
Device2
Combination product1
Procedure1

Sponsor type

Industry22
Other academic3
WCM (investigator-initiated)2

Start date

Has results posted7

Recurrence×Clear all

Showing 1–20 of 27 studiesSort:

RecruitingInterventional · Phase 1NCT02074839 ↗
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Gail J RobozPI
Intervention
Drug: AG-120
Dates
Mar 2014 – Dec 2026 (est.)

FiltersClear all

Status

Recruiting8
Active, not recruiting5
Completed8
Terminated6

Study type

Interventional25
Expanded access2

Phase

Phase 18
Phase 1/26
Phase 25
Phase 32
Not applicable2
Not reported2

Investigator

Gail J Roboz4
John Allan3
Pinkal Desai3
Ruben Niesvizky3
Ellen K. Ritchie2

Show all 17Show fewer

Department

Medicine25
Neurology2

Condition

Recurrence27
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50Show fewer

Intervention type

Drug23
Biological3
Device2
Combination product1
Procedure1

Sponsor type

Industry22
Other academic3
WCM (investigator-initiated)2

Start date

Has results posted7

Recurrence×Clear all

Showing 1–20 of 27 studiesSort:

RecruitingInterventional · Phase 1NCT02074839 ↗
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Gail J RobozPI
Intervention
Drug: AG-120
Dates
Mar 2014 – Dec 2026 (est.)

Phase 2/3

Mateo Mejia Saldarriaga1

Multiple Myeloma32
Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Overweight15
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Fibrosis9
Liver Diseases9
Carcinoma, Renal Cell8

Sponsor

Agios Pharmaceuticals, Inc.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

RecruitingInterventional · Not applicableNCT02235857 ↗

Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System

Darshana M DadhaniaPI

Intervention: Device: LIPOSORBER® LA-15 System
Dates: May 2015 – Sep 2027 (est.)
Sponsor: Kaneka Pharma America Corporation

Focal Segmental Glomerulosclerosis

Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Pinkal DesaiPI

Intervention: Drug: Imetelstat Sodium · Drug: Placebo
Dates: Jan 2016 – Oct 2023· Results posted
Sponsor: Geron Corporation

Myelodysplastic Syndromes

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mg
Dates: Oct 2016 – May 2024· Results posted
Sponsor: Celgene Corporation

Multiple Myeloma

RecruitingInterventional · Phase 2NCT02974647 ↗

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Jia RuanPI

Intervention: Drug: Ruxolitinib
Dates: Nov 2016 – Nov 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Lymphoma

Active, not recruitingInterventional · Phase 1/2NCT04086264 ↗

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Gail J RobozPI

Intervention: Drug: Azacitidine · Drug: IMGN632 · Drug: Venetoclax
Dates: Nov 2019 – Feb 2027 (est.)
Sponsor: AbbVie Inc.

Acute Myeloid Leukemia

RecruitingInterventional · Phase 1/2NCT04150497 ↗

Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

Gail J RobozPI

Intervention: Biological: UCART22 · Biological: CLLS52
Dates: Oct 2019 – Jun 2026 (est.)
Sponsor: Cellectis, Inc

B-cell Acute Lymphoblastic Leukemia

Active, not recruitingInterventional · Phase 1NCT04279847 ↗

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Ellen K. RitchiePI

Intervention: Drug: INCB057643 · Drug: Ruxolitinib
Dates: Feb 2021 – Apr 2027 (est.)
Sponsor: Incyte Corporation

MyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more

Active, not recruitingInterventional · Phase 1NCT04420754 ↗

A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer

Sebastian A. MayerPI

Intervention: Biological: AIC100 CAR T Cells
Dates: Sep 2020 – Aug 2026 (est.)
Sponsor: AffyImmune Therapeutics Inc.

Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer

RecruitingInterventional · Phase 1NCT05798897 ↗

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)

Caitlin K GribbinPI

Intervention: Drug: MT-601
Dates: Jan 2023 – Feb 2028 (est.)
Sponsor: Marker Therapeutics, Inc.

Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more

RecruitingInterventional · Phase 3NCT06615479 ↗

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Mateo Mejia SaldarriagaPI

Intervention: Drug: BMS-986393 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Carfilzomib
Dates: Mar 2025 – Dec 2027 (est.)
Sponsor: Juno Therapeutics, Inc.

Relapsed or Refractory Multiple Myeloma (RRMM)

RecruitingInterventional · Phase 1/2NCT06634589 ↗

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

John AllanPI

Intervention: Drug: Tacabrutideg · Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Mosunetuzumab · Drug: Glofitamab · Drug: Obinutuzumab
Dates: Nov 2024 – Dec 2028 (est.)
Sponsor: BeiGene USA

B-cell MalignancyRelapsed CancerRefractory Cancer+1 more

RecruitingInterventional · Phase 1NCT07082803 ↗

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Erin MulveyPI

Intervention: Drug: TLN-121 · Drug: zeprumetostat (TLN-254)
Dates: Jun 2025 – Sep 2030 (est.)
Sponsor: Treeline Biosciences INC

LymphomaLymphoma, Non Hodgkin

TerminatedInterventional · Phase 1NCT03218683 ↗

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

Pinkal DesaiPI

Intervention: Drug: AZD5991 · Drug: AZD5991 + Venetoclax
Dates: Aug 2017 – Oct 2021
Sponsor: AstraZeneca Pharmaceuticals LP

Relapsed or Refractory Acute Myeloid Leukemia (AML)

CompletedInterventional · Phase 2NCT03557359 ↗

A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents

Howard Alan FinePI

Intervention: Drug: Nivolumab
Dates: Jun 2018 – Sep 2022· Results posted
Sponsor: Columbia University

Gliomas

TerminatedInterventional · Phase 1/2NCT03572634 ↗

A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: TP-0903 · Combination product: TP-0903 and ibrutinib combination therapy
Dates: Jun 2019 – Jan 2020· Results posted
Sponsor: Tolero Pharmaceuticals Inc.

Chronic Lymphocytic LeukemiaCLLSLL+1 more

CompletedInterventional · Phase 1NCT03625505 ↗

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Ellen K. RitchiePI

Intervention: Drug: Venetoclax · Drug: Gilteritinib
Dates: Oct 2018 – Aug 2021
Sponsor: AbbVie Inc.

Acute Myeloid Leukemia (AML)

CompletedInterventional · Phase 3NCT03651128 ↗

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Roger N PearsePI

Intervention: Biological: bb2121 · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Lenalidomide · Drug: Carfilzomib · Drug: Elotuzumab
Dates: Apr 2019 – Apr 2026
Sponsor: Celgene Corporation

Multiple Myeloma

TerminatedInterventional · Phase 2NCT03679624 ↗

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

John AllanPI

Intervention: Drug: Ibrutinib · Drug: Daratumumab
Dates: Jul 2020 – Sep 2020· Results posted
Sponsor: Weill Medical College of Cornell University

Waldenstrom MacroglobulinemiaWaldenstrom's DiseaseWaldenström+5 more

TerminatedInterventional · Phase 1/2NCT04113616 ↗

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Gail J RobozPI

Intervention: Drug: KRT-232 · Drug: Cytarabine · Drug: Decitabine
Dates: Sep 2019 – Sep 2023
Sponsor: Kartos Therapeutics, Inc.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

‹ Prev1 2 Next ›